Journal ArticleDOI
Intracoronary delivery of mesenchymal stem cells reduces proarrhythmogenic risks in swine with myocardial infarction
Reads0
Chats0
TLDR
This study provides strong evidence that MSC infusion via intracoronary route does not cause VAs but tends to reduce the risk of malignant VAs.Abstract:
The electrophysiological consequences of mesenchymal stem cell (MSC) therapy in ischemic heart disease have not been fully understood. Swine myocardial infarction (MI) model by intracoronary balloon occlusion received MSC solution or 0.9% NaCl. Six weeks later, heart rate turbulence (HRT), dispersion of action potential durations (APD) and repolarization time (RT) (APDd and RTd), slope of APD reconstitution curve and programmed electrical stimulation were used to evaluate the ventricular arrhythmic risks. MSC treatment could significantly ameliorate the abnormal HRT, APD90, APDd, RT and RTd. The slope of APD reconstitution curve in MSC group was higher than control group but lower than MI group. MSC therapy markedly reduced inducible malignant ventricular arrhythmias (VAs), and improved impaired cardiac performances and cardiac fibrosis. This study provides strong evidence that MSC infusion via intracoronary route does not cause VAs but tends to reduce the risk of malignant VAs.read more
Citations
More filters
Journal ArticleDOI
Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).
TL;DR: This in-depth review is an attempt to summarize the major sources of mesenchymal stem cells involved in myocardial regeneration, the significant mechanisms involved in the process with a focus on studies conducted in the last 6 years and the challenges that remain to be addressed.
Journal ArticleDOI
Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-Analysis of Large Animal Studies
J. E. C. Eding,Hanna M. Vesterinen,Tycho Ids Gijsbert van der Spoel,Emily S. Sena,Henricus J. Duckers,Pieter A. Doevendans,Malcolm R. Macleod,Steven Anton Jozef Chamuleau +7 more
TL;DR: In this article, a meta-analysis of preclinical data of cell therapy for ischemic heart disease was performed, which showed a significant improvement in mean left ventricular ejection fraction in treated compared with control animals.
Journal ArticleDOI
Mesenchymal stem cells for cardiovascular regeneration.
TL;DR: In vivo and in vitro evidence suggests that MSCs can also differentiate into cardiomyogenic and vasculogenic lineages, offering another cell source for cardiovascular regeneration, as well as their limitations that may prevent them from being effectively used in the clinic.
Journal ArticleDOI
Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases.
TL;DR: An overview of known mechanisms by which MSCs mediate their anti-fibrotic actions and in relation to animal models of pulmonary, liver, renal and cardiac fibrosis is provided.
Journal ArticleDOI
Quantitative Assessment of Sialo-Glycoproteins and N-Glycans during Cardiomyogenic Differentiation of Human Induced Pluripotent Stem Cells.
Sarah A. Konze,Samanta Cajic,Astrid Oberbeck,René Hennig,Andreas Pich,Erdmann Rapp,Falk F. R. Buettner +6 more
TL;DR: Analysis of the N‐glycome by capillary gel electrophoresis revealed three novel structures comprising β1,3‐linked galactose, α2,6‐linked sialic acid and complex fucosylation, which are proposed to be characteristic of early, immature CMs.
References
More filters
Journal ArticleDOI
Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure
Emerson C. Perin,Hans F. Dohmann,Radovan Borojevic,Suzana A. Silva,Andre L.S. Sousa,Claudio Tinoco Mesquita,Maria Isabel D. Rossi,Antonio Carlos Carvalho,Hélio S. Dutra,Hans J.F. Dohmann,Guilherme V. Silva,Luciano Belem,Ricardo Vivacqua,Fernando Oswaldo Dias Rangel,Roberto Esporcatte,Yong-Jian Geng,William K. Vaughn,Joao A.R. Assad,Evandro Tinoco Mesquita,James T. Willerson +19 more
TL;DR: The present study demonstrates the relative safety of intramyocardial injections of bone marrow–derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.
Journal ArticleDOI
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
Stefan Janssens,Christophe Dubois,Jan Bogaert,Koen Theunissen,Christophe Deroose,Walter Desmet,Maria Kalantzi,Lieven Herbots,Peter Sinnaeve,Joseph Dens,Johan Maertens,Frank Rademakers,Steven Dymarkowski,Olivier Gheysens,Johan Van Cleemput,Guy Bormans,Johan Nuyts,Ann Belmans,Luc Mortelmans,Marc Boogaerts,Frans Van de Werf +20 more
TL;DR: Intracoronary transfer of autologous bone marrow cells within 24 h of optimum reperfusion therapy does not augment recovery of global LV function after myocardial infarction, but could favourably affect infarct remodelling.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction
Joshua M. Hare,Jay H. Traverse,Timothy D. Henry,Nabil Dib,Robert K. Strumpf,Steven P. Schulman,Gary Gerstenblith,Anthony N. DeMaria,Ali E. Denktas,Roger Gammon,James B. Hermiller,Mark A. Reisman,Gary L. Schaer,Warren Sherman +13 more
TL;DR: This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients and indicates intravenousAllogeneic hMSCs are safe in patients after acute MI.
Journal ArticleDOI
Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction
Philippe Menasché,Albert Hagège,Jean-Thomas Vilquin,Michel Desnos,Eric Abergel,Bruno Pouzet,Alain Bel,Sorin Sarateanu,Marcio Scorsin,Ketty Schwartz,Patrick Bruneval,Marc Benbunan,Jean-Pierre Marolleau,Denis Duboc +13 more
TL;DR: These preliminary data suggest the feasibility and safety of autologous skeletal myoblast transplantation in severe ischemic cardiomyopathy, with the caveat of an arrhythmogenic potential, and new-onset contraction of akinetic and nonviable segments suggests a functional efficacy that requires confirmation by randomized studies.
Journal ArticleDOI
Slow conduction in the infarcted human heart. 'Zigzag' course of activation.
J. M. T. de Bakker,F. J. L. Van Capelle,Michiel J. Janse,Sara Tasseron,J. T. Vermeulen,N. de Jonge,Jaap R. Lahpor +6 more
TL;DR: Slow conduction perpendicular to the fiber direction in infarcted myocardial tissue is caused by a "zigzag" course of activation at high speed.